These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 7665214)

  • 1. A non-human primate study (baboon; Papio hamadryas) to determine if a long-acting progestogen, levonorgestrel butanoate, combined with a long-acting androgen, testosterone buciclate, can suppress spermatogenesis: II. Efficacy study.
    Goncharov NP; Katzia GV; Butnev VU; Gorlushkin VM; Waites GM
    Int J Androl; 1995 Apr; 18(2):83-7. PubMed ID: 7665214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A non-human primate study (baboon; Papio hamadryas) to determine if a long-acting progestogen, levonorgestrel butanoate, combined with a long-acting androgen, testosterone buciclate, can suppress spermatogenesis: I. Dose-finding study.
    Goncharov NP; Katzia GV; Butnev VU; Richkor EG; Matikainen T; Waites GM
    Int J Androl; 1995 Apr; 18(2):75-82. PubMed ID: 7665213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the ability of levonorgestrel butanoate alone, or in combination with testosterone buciclate, to suppress spermatogenesis in the bonnet monkey (Macaca radiata).
    Rajalakshmi M; Pal PC; Jeyaraj DA; Sharma RS; Griffin PD; Waites GM
    Int J Androl; 2000 Apr; 23(2):95-105. PubMed ID: 10762435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach.
    Bebb RA; Anawalt BD; Christensen RB; Paulsen CA; Bremner WJ; Matsumoto AM
    J Clin Endocrinol Metab; 1996 Feb; 81(2):757-62. PubMed ID: 8636300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intramuscular testosterone enanthate plus very low dosage oral levonorgestrel suppresses spermatogenesis without causing weight gain in normal young men: a randomized clinical trial.
    Anawalt BD; Amory JK; Herbst KL; Coviello AD; Page ST; Bremner WJ; Matsumoto AM
    J Androl; 2005; 26(3):405-13. PubMed ID: 15867009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
    Behre HM; Baus S; Kliesch S; Keck C; Simoni M; Nieschlag E
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone.
    Gonzalo IT; Swerdloff RS; Nelson AL; Clevenger B; Garcia R; Berman N; Wang C
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3562-72. PubMed ID: 12161475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
    Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Male hormonal contraception: suppression of spermatogenesis by injectable testosterone undecanoate alone or with levonorgestrel implants in chinese men.
    Gui YL; He CH; Amory JK; Bremner WJ; Zheng EX; Yang J; Yang PJ; Gao ES
    J Androl; 2004; 25(5):720-7. PubMed ID: 15292101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations.
    Wallace EM; Gow SM; Wu FC
    J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production.
    Matsumoto AM
    J Clin Endocrinol Metab; 1990 Jan; 70(1):282-7. PubMed ID: 2104626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel male hormonal contraceptive combinations: the hormonal and spermatogenic effects of testosterone and levonorgestrel combined with a 5alpha-reductase inhibitor or gonadotropin-releasing hormone antagonist.
    Matthiesson KL; Amory JK; Berger R; Ugoni A; McLachlan RI; Bremner WJ
    J Clin Endocrinol Metab; 2005 Jan; 90(1):91-7. PubMed ID: 15509637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levonorgestrel implants enhanced the suppression of spermatogenesis by testosterone implants: comparison between Chinese and non-Chinese men.
    Wang C; Wang XH; Nelson AL; Lee KK; Cui YG; Tong JS; Berman N; Lumbreras L; Leung A; Hull L; Desai S; Swerdloff RS
    J Clin Endocrinol Metab; 2006 Feb; 91(2):460-70. PubMed ID: 16278260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intramuscular testosterone undecanoate with or without oral levonorgestrel: a randomized placebo-controlled feasibility study for male contraception.
    Kamischke A; Plöger D; Venherm S; von Eckardstein S; von Eckardstein A; Nieschlag E
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):43-52. PubMed ID: 10931079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations.
    Anawalt BD; Bebb RA; Bremner WJ; Matsumoto AM
    J Androl; 1999; 20(3):407-14. PubMed ID: 10386821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
    Tom L; Bhasin S; Salameh W; Steiner B; Peterson M; Sokol RZ; Rivier J; Vale W; Swerdloff RS
    J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens.
    Bagatell CJ; Matsumoto AM; Christensen RB; Rivier JE; Bremner WJ
    J Clin Endocrinol Metab; 1993 Aug; 77(2):427-32. PubMed ID: 8345047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens.
    Guerin JF; Rollet J
    Int J Androl; 1988 Jun; 11(3):187-99. PubMed ID: 2970439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testosterone-induced inhibition of spermatogenesis is more closely related to suppression of FSH than to testicular androgen levels in the cynomolgus monkey model (Macaca fascicularis).
    Weinbauer GF; Schlatt S; Walter V; Nieschlag E
    J Endocrinol; 2001 Jan; 168(1):25-38. PubMed ID: 11139767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of human spermatogenesis by testosterone implants.
    Handelsman DJ; Conway AJ; Boylan LM
    J Clin Endocrinol Metab; 1992 Nov; 75(5):1326-32. PubMed ID: 1430094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.